iHealthScreen
- Company typePrivate
- Founded2015
- HeadquartersRichmond Hill, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
iHealthScreen firmographics
Firmographics- Name
- iHealthScreen
- Legal name
- iHealthScreen Inc.
- Website
- https://ihealthscreen.org
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
iHealthScreen industry classification
Industry- Product category
- Ophthalmic AI Screening Software
- NAICS
- Ophthalmic Goods Manufacturing (339115), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Offices of Optometrists (62132)
- SIC
- Ophthalmic Goods (3851), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography) (HLAHAJAB)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Vision & Ophthalmic Diagnostic Centers (Optometry/OCT/Retinal Imaging) (HLAFAKAI)
Keywords
Where iHealthScreen is headquartered
LocationHeadquarters
- HQ city
- Richmond Hill
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
iHealthScreen business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Revenue model
- Per-Test Screening Fees: B2B revenue from healthcare providers and clinics using the iPredict screening system on a per-test or subscription basis. Each screening test priced at approximately $50 per patient.
- EHR and Telemedicine Platform Services: Revenue generated from integration and licensing of the iPredict and MyHealth EHR/telemedicine platforms to healthcare facilities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Usage-based | Pay-as-you-go | Per-Test Screening — ~$50 per patient screened |
| Subscription | Annual | Enterprise Subscription — quote-based pricing for high-volume healthcare providers |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels3 records
iHealthScreen product offering
Product offeringCore offering
iHealthScreen develops and sells the iPredict AI software platform, which analyzes retinal color fundus photographs to automatically screen for three blinding eye diseases — Diabetic Retinopathy, Age-related Macular Degeneration, and Glaucoma — simultaneously, delivering diagnostic results in under 5 minutes with reported accuracy above 95%. The platform also includes risk prediction tools for stroke, heart attack, and diabetes, EHR solutions (iPredict and MyHealth), telemedicine capabilities, and specialized retinal image analyzers (RePPA, ReVA, OCT Inspector) sold to healthcare providers, hospital systems, and government screening programs.
Product overview
iHealthScreen offers a unified AI-driven healthcare platform centered on the iPredict system, which provides automated screening for three blinding eye diseases (Diabetic Retinopathy, Age-related Macular Degeneration, and Glaucoma) along with health risk prediction tools for stroke, heart attack, and diabetes. The platform includes EHR solutions (iPredict for USA, MyHealth for Bangladesh), telemedicine capabilities, and specialized image analysis tools (RePPA, ReVA, OCT Inspector) that process retinal images using deep learning algorithms to deliver diagnostic results in under 60 seconds.
Differentiator
Problem solved
Functional benefit
Brands
- iPredict: AI-based eye screening system for automated diagnosis of AMD, DR, and glaucoma; also includes prediction apps for diabetes, stroke, and heart attack
- MyHealth
- RePPA
- ReVA
Products and services
- iPredict AI-based telemedicine platform providing fully automated screening for Diabetic Retinopathy, AMD, and Glaucoma plus health risk prediction for stroke, heart attack, and diabetes. Processes retinal images and delivers diagnostic results in under 60 seconds; CE certified and FDA 510(k) submitted.
- iPredict DR (Diabetic Retinopathy) Automated AI system for early diagnosis of Diabetic Retinopathy using retinal imaging. Reports up to 98.48% accuracy, 97.32% sensitivity, and 98.75% specificity for referable DR; FDA 510(k) submission in progress.
- iPredict AMD (Age-related Macular Degeneration) Automated AI system for screening Age-related Macular Degeneration in adults 50+. Reports 99.2% accuracy with 98.9% sensitivity and 99.5% specificity for referrable AMD; FDA 510(k) submitted.
- iPredict Glaucoma Automated AI system for glaucoma suspect detection based on abnormal optic discs. Reports 89.67% accuracy with 83.33% sensitivity and 93.89% specificity; TGA, MHRA, and UAE Health approved.
- iPredict Diabetes AI-powered risk prediction tool that foretells the risk of diabetes and provides hassle-free information to patients and doctors with simple results and easy-to-understand suggestions.
- iPredict Stroke AI-based stroke risk prediction tool that foretells the risk of stroke and provides information in a hassle-free manner to both patient and doctor.
- iPredict Heart Attack AI-based myocardial infarction (heart attack) risk prediction tool that foretells heart attack risk and provides information to patients and doctors.
- Electronic Health Record (EHR) Solutions Digital version of traditional paper-based medical records with telemedicine integration, digital prescription, video consultation, and patient data history management. Available as iPredict (USA) and MyHealth (Bangladesh).
- Telemedicine Platform Telemedicine app enabling online appointments, video/audio consultations with doctors, online prescriptions, and specialist search. Connects patients with healthcare providers remotely.
- RePPA (Retinal Pathology Progression Analyzer) Image analysis tool for analyzing retinal pathology progression in Diabetic Retinopathy, AMD, and other eye diseases. Features image calibration, vessel/optic disk analysis, drusen analysis, and two-image registration at different times.
- ReVA (Retinal Vessel Analyzer) Automated retinal blood vessel analysis tool to determine individual risk for systemic diseases. Features optic disc detection, blood vessel detection, vessel width measurement, image grading, and CRAE/CRVE computation.
- OCT Inspector Optical Coherence Tomography analysis tool for finding and monitoring retinal diseases through automated segmentation of retinal layers in 2D and 3D from SD-OCT images.
- MyHealth Telemedicine platform variant deployed in Bangladesh, offering telemedicine services, AI-based eye disease screening, and electronic health records for the Bangladesh market.
Quantifiable outcome
- 95%+ screening accuracy for DR, AMD, and glaucoma detection
- +3 more outcomes
Companies that use iHealthScreen
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
iHealthScreen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability4 records
Feature3 records
iHealthScreen partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and minor.
- Mount Sinai Hospital — New York Eye and Ear InfirmarycoreClinical trial collaboration with Mount Sinai Hospital (New York Eye and Ear Infirmary) for validation of the AI-based screening system. Mount Sinai serves as a key clinical validation site in the USA, having screened patients for DR, AMD, and glaucoma using the iPredict system.
- Diabetic Association of Bangladesh (BADAS)corePartnership with BADAS for large-scale diabetic eye disease screening in Bangladesh, targeting 5 million diabetic patients. This is a flagship deployment partnership enabling population-level screening in a high-need geography.
- Bangladesh Diabetes SocietycoreCollaborative screening partnership with Bangladesh Diabetes Society to screen 5 million diabetics across Bangladesh for diabetic retinopathy and other eye diseases, leveraging the iPredict AI screening platform.
- Innovation Place Bangladesh (IPB)minorSister concern and strategic partner operating the Bangladesh operations, supporting the deployment of screening programs and market expansion in the Bangladesh region.
Scale indicators7 records
Recent moves9 records
Expansion highlights5 records
iHealthScreen competitors and assessment
Company assessmentBroad incumbents
- Google Health (Retinal AI): Has published foundational research on retinal AI for systemic disease prediction (cardiovascular risk from fundus images). A large incumbent with research overlap that could enter commercial ophthalmic AI screening.
- Heidelberg Engineering: Premium retinal imaging and OCT systems used by ophthalmologists worldwide with emerging AI-enabled diagnostic tools. Comparable as an incumbent imaging platform increasingly augmented with AI screening.
- Topcon Healthcare: Major ophthalmic imaging hardware and software provider (fundus cameras, OCT) integrating AI screening into its devices. Comparable in retinal imaging workflows with growing AI-screening capability competitive with iPredict.
- Carl Zeiss Meditec: Global ophthalmic device leader producing fundus cameras, OCT, and integrated diagnostic platforms. Comparable as a broad incumbent in ophthalmic imaging where AI screening increasingly sits on top of their hardware.
Emerging players
- Thirona: Specialist in AI-based medical image analysis including retinal OCT and fundus image quantification. Comparable in applying deep learning to retinal image analysis for clinical decision support.
- Mediwhale: AI company using retinal images to predict systemic disease risk (cardiovascular, kidney, age-related conditions). Comparable in expanding retinal imaging beyond ophthalmology into systemic-disease prediction.
Direct peers
- Digital Diagnostics (IDx-DR): Pioneer in autonomous AI diagnosis of diabetic retinopathy; IDx-DR was the first FDA-cleared autonomous AI diagnostic in any specialty of medicine (acquired by GE HealthCare). Directly comparable in target disease (DR) and autonomous-screening positioning.
- RetinaLyze: AI-based retinal image analysis platform for DR, AMD, and glaucoma screening sold to optometrists and primary care in Europe and select international markets. Closely comparable in product breadth and customer base.
- AEYE Health: FDA-cleared autonomous AI for DR screening using retinal imaging, with similar single-image, point-of-care workflow in primary-care settings. Direct competitor for US and international screening deployments.
- Eyenuk (EyeArt): FDA-cleared AI platform for autonomous detection of DR and other retinal diseases, competing head-to-head with iHealthScreen in primary-care DR screening workflows globally.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
iHealthScreen social profiles
Digital presenceiHealthScreen compliance and trust
Trust signalCompliance6 records
iHealthScreen financial estimates
Financial estimateRevenue estimate
Valuation estimate
iHealthScreen leadership team
Management profileNumber of profiles
Profiles6 records
iHealthScreen subsidiaries and ownership
Company hierarchySubsidiaries3 records
iHealthScreen funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
iHealthScreen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about iHealthScreen
What does iHealthScreen do?
iHealthScreen develops and sells the iPredict AI software platform, which analyzes retinal color fundus photographs to automatically screen for three blinding eye diseases — Diabetic Retinopathy, Age-related Macular Degeneration, and Glaucoma — simultaneously, delivering diagnostic results in under 5 minutes with reported accuracy above 95%. The platform also includes risk prediction tools for stroke, heart attack, and diabetes, EHR solutions (iPredict and MyHealth), telemedicine capabilities, and specialized retinal image analyzers (RePPA, ReVA, OCT Inspector) sold to healthcare providers, hospital systems, and government screening programs.
Is iHealthScreen a public or private company?
iHealthScreen is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was iHealthScreen founded?
iHealthScreen was founded in 2015. It employs 11 to 50 people.
Where is iHealthScreen based?
iHealthScreen is headquartered in Richmond Hill, United States, in the North America region.
How does iHealthScreen make money?
Two revenue lines are on record. Per-Test Screening Fees are the primary driver. The others are EHR and Telemedicine Platform Services.
Who are iHealthScreen's main competitors?
Broad incumbents on record are Google Health (Retinal AI), Heidelberg Engineering, Topcon Healthcare and Carl Zeiss Meditec. Emerging players are Thirona and Mediwhale. Direct peers are Digital Diagnostics (IDx-DR), RetinaLyze, AEYE Health and Eyenuk (EyeArt).
Does iHealthScreen have an API?
No public API is recorded for iHealthScreen.
What industry is iHealthScreen in?
iHealthScreen's product category is Ophthalmic AI Screening Software. Its primary akta.pro industry code is HLAHAJAB, Retinal Imaging & OCT Systems (OCT/OCTA, Fundus Cameras, Fluorescein/ICG Angiography), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 339115 and its SIC code is 3851.